Status:
COMPLETED
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Lead Sponsor:
Stemline Therapeutics, Inc.
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whos...
Detailed Description
This is an international, multicenter, randomized, open-label, active-controlled, event-driven, Phase 3 clinical study comparing the efficacy and safety of elacestrant to the SoC options of fulvestran...
Eligibility Criteria
Inclusion
- Critical
- Participants with proven diagnosis of adenocarcinoma of the breast with evidence of either locally advanced disease not amenable to resection or radiation therapy with curative intent or metastatic disease not amenable to curative therapy.
- Participants must be appropriate candidates for endocrine monotherapy
- Participants must have measurable disease or bone only disease with evaluable lesions
- Female or male participants age ≥ 18 years; female participants must be postmenopausal women, and male participants must not allow pregnancy with their sperm (abstain, do not donate sperm, et cetera).
- Participants must have ER+ and HER2- tumor status
- Participants must have previously received at least one and no more than two lines of endocrine therapy for advanced/metastatic breast cancer and meet additional previous treatment criteria.
- Participants must have received prior treatment with a CDK4/6 inhibitor in combination with either fulvestrant or an aromatase inhibitor (AI) for advanced/metastatic breast cancer (mBC).
- Participants may have received no more than one line of chemotherapy in the advanced/metastatic setting.
- Critical
Exclusion
- Prior treatment with elacestrant or other investigational selective estrogen receptor degrader (SERD) or ER antagonist (D-0502, GDC-0810, GDC-0927, GDC-9545, G1T-48, LSZ102, AZD9496, SAR439859, ZN-c5, H3B-6545, bazedoxifene, lasofoxifene).
- Prior anticancer or investigational drug treatment within the following windows:
- Fulvestrant treatment \< 42 days before first dose of study drug
- Any endocrine therapy \< 14 days before first dose of study drug
- Chemotherapy \< 21 days before first dose of study drug
- Any investigational anti-cancer drug therapy \< 28 days or five half-lives (whichever is shorter) before the first dose of study drug. Enrollment of participants whose most recent therapy was an investigational agent should be discussed with the Sponsor
- Bisphosphonates or RANKL inhibitors initiated or dose changed \< 3 months prior to first dose of study drug
- Presence of symptomatic visceral disease as defined in protocol.
Key Trial Info
Start Date :
May 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 22 2024
Estimated Enrollment :
478 Patients enrolled
Trial Details
Trial ID
NCT03778931
Start Date
May 10 2019
End Date
August 22 2024
Last Update
September 15 2025
Active Locations (244)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Arizona Cancer Center
Tucson, Arizona, United States, 85724
2
St Bernard's Cancer Care
Jonesboro, Arkansas, United States, 72401
3
St. Jude Heritage Healthcare
Fullerton, California, United States, 92835
4
Adventist Health Glendale
Glendale, California, United States, 91206